Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy

Nakao, Yukimichi; Tamauchi, Satoshi; Yoshikawa, Nobuhisa; Suzuki, Shiro; Kajiyama, Hiroaki; Kikkawa, Fumitaka

doi:10.1159/000506446

Cited by 8 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first was a case of small cell carcinoma, for which TC and bevacizumab therapy without bevacizumab single maintenance therapy was administered, and the status of no recurrence was maintained at 24 months after TC and bevacizumab therapy. 21 The second was a case of small-cell carcinoma, for which a paclitaxel, cisplatin, and bevacizumab regimen without bevacizumab single maintenance therapy was administered; however, the time from discontinuation of the therapy to recurrence was 2 months and the patient was alive at 16 months after recurrence. 22 No adverse events associated with bevacizumab were reported in these two cases; however, the two patients were alive and were not followed up until death.…”

Section: Discussionmentioning

confidence: 99%

“…23 These findings indicate that the TC regimen is less effective than the EP or IP regimens, and that the EP or IP regimens should be recommended as the first-line chemotherapy for NEC of the cervix. In the two abovementioned case reports, 21,22 the EP regimen was administered as the first-line treatment, and both cases had a relatively good course. The TC plus Abbreviations: OS, overall survival; PFI, platinum-free interval; PFS, progression-free survival.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Paclitaxel‐carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series

Kotaka,

Kondo,

Kawai

et al. 2023

J of Obstet and Gynaecol

Self Cite

View full text Add to dashboard Cite

AimThere is no conclusive data on the prognosis of patients who receive paclitaxel‐carboplatin (TC) plus bevacizumab therapy for advanced neuroendocrine carcinoma (NEC) of the uterine cervix, a rare histological subtype of cervical cancer. Thus, the aim of this study was to determine the efficacy of TC chemotherapy plus bevacizumab and bevacizumab single maintenance therapy for advanced NEC of the cervix.MethodsThis was a retrospective review of patients who received TC plus bevacizumab therapy for metastatic, recurrent, or persistent NEC of the cervix at seven institutions between 2015 and 2020. Relevant data were extracted from the patients' medical records and analyzed.ResultsSeven patients, including six with small‐cell NEC and one with large‐cell NEC, were included for analysis. Three patients received bevacizumab single maintenance therapy following TC plus bevacizumab therapy, whereas four patients did not receive bevacizumab single maintenance therapy. The median overall survival and progression‐free survival of the patients who received bevacizumab single maintenance therapy were longer than those of the patients who did not receive the therapy (34 months vs. 10.5 months and 19 months vs. 5 months, respectively). However, the patients who received bevacizumab single maintenance therapy had received cisplatin‐based chemotherapy previously.ConclusionsOn the premise that cisplatin‐based chemotherapy is administered as the first‐line treatment for advanced NEC of the cervix, bevacizumab single maintenance therapy following TC plus bevacizumab may be considered the second‐ or third‐line treatment. However, the risk of adverse events, such as intestinal perforation, should be discussed with patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Paclitaxel‐carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series

Kotaka,

Kondo,

Kawai

et al. 2023

J of Obstet and Gynaecol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Studies have shown that EP is less toxic than VAC. In addition, the EP, TP, or TC regimen has been proven effective in specific clinical situations [50,51]. However, Wang discovered that the combination of etoposide and platinum did not result in an improved overall survival rate after surgery when compared to the combination of platinum and paclitaxel (p = 0.71).…”

Section: Multimodality Therapymentioning

confidence: 99%

Advances in Research, Diagnosis, and Treatment of Neuroendocrine Cervical Carcinoma: A Review

Ren,

Wu,

et al. 2023

Oncol Rev.

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NENs) were classified separately in the 5th edition (2020) of the World Health Organization (WHO) classification of female genital malignancies. Cervical neuroendocrine carcinoma (NEC) is distinguished by its low incidence, high invasiveness, early local dissemination, and distant metastases. The purpose of this review is to outline the achievements in pathology, diagnostics, gene sequencing, and multi-modality treatment of cervical NEC.

show abstract

“…The patient was treated with 8 cycles of TC + bevacizumab and achieved CR with a progression-free survival (PFS) of more than 24 months. 29 Although the evidence from case reports is weak, their results indicate the potential benefits of anti-angiogenic drugs in SCCC treatment.…”

Section: Introductionmentioning

confidence: 99%

Real-world Efficacy Data on Anti-Angiogenic Drugs in Recurrent Small Cell Cervical Carcinoma: A Retrospective Study

Qiu

Yan

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Objective Small cell carcinoma of the cervix (SCCC) is rare but extremely aggressive and resistant to current therapies. We herein evaluate the efficacy of bevacizumab, apatinib, and anlotinib in recurrent/metastatic SCCC patients in a real-world setting. Methods Recurrent/metastatic SCCC patients were recruited between January 2013 and July 2020. Baseline characteristics were extracted from medical records, and patients were divided into an anti-angiogenic group and non-anti-angiogenic group. The efficacy of treatments was determined using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Kaplan–Meier analysis was performed for survival analysis. Results Sixteen patients received anti-angiogenic drugs after tumor recurrence/metastasis; of them, 10 cases received them as first-line treatment, 5 cases as second-line treatment, and 1 case as fourth-line treatment. Another 23 patients received traditional therapies, including surgery, chemotherapy, and radiotherapy. The use of anti-angiogenic drugs in first-line treatment significantly prolonged progression-free survival (PFS) compared to the controls, with a median PFS of 8 months (2-20 months) and 3 months (1-10 months), respectively ( P = .025). This trend was also notable in patients who started anti-angiogenic treatment after the second-line recurrence/metastasis. However, there was no benefits for overall survival (OS) in either the 10 first-line cases or all 16 cases ( P = .499 and .31, respectively). Both bevacizumab and small molecule drugs (apatinib and anlotinib) presented similar efficacy in SCCC patients. Conclusions At present, this is the largest cohort study that provides real-world data, showing that anti-angiogenic regimens could significantly prolong PFS in recurrent/metastatic SCCC. Aside from bevacizumab, the novel oral small molecule drugs provide more choices with similar efficacy. These findings warrant further validation in well-designed future studies.

show abstract

Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy

Cited by 8 publications

References 15 publications

Paclitaxel‐carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series

Paclitaxel‐carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series

Advances in Research, Diagnosis, and Treatment of Neuroendocrine Cervical Carcinoma: A Review

Real-world Efficacy Data on Anti-Angiogenic Drugs in Recurrent Small Cell Cervical Carcinoma: A Retrospective Study

Contact Info

Product

Resources

About